



110 West Cliff Avenue
Spokane, WA 99204

PATHOLOGY ASSOCIATES
MEDICAL LABORATORIES

509.755.8600
800.541.7891

TEST ALERT

Number 254, July 15, 2003

The following tables reflect revisions only; other existing data remain unchanged.

Test Method GA Workpar / SQ Code CPT Code(s)	Specimen Requirements	Reference Ranges	Comments Effective Date
14-3-3 PROTEIN, CSF ICMA 1433PC / 1433PC 83520 (Mayo)	1 mL CSF in sterile, screw-cap vial. Store and transport refrigerated.	Normal LT 2.0 ng/mL Indeterminate 2.0-3.9 Elevated 4.0 or more This test was developed and its performance characteristics determined by Laboratory Medicine and Pathology, Mayo Clinic Rochester. It has not been cleared or approved by the U.S. Food & Drug Administration.	NEW PROCEDURE Effective 8-19-03.
ATRIAL NATRIURETIC FACTOR RIA after cartridge extraction ANFP / ANFP 83519 (Mayo)	2.2 mL frozen EDTA plasma (lavender top tube) from a fasting patient drawn before noon. Cardiovascular medication, including beta-antagonists, calcium antagonists, cardiac glycosides, diuretics, and vasodilators, should be withheld for 24 hours prior to drawing specimen. Prechill lavender-top (EDTA) tubes at 4°C before drawing. Put in wet ice for 10 minutes immediately after drawing. Centrifuge in a refrigerated centrifuge or chilled centrifuged cups. Remove plasma from the cells, put in separate plastic tube, and freeze. Store and transport frozen.	20-77 pg/mL	NEW PROCEDURE Effective 8-19-03.
BIOTINIDASE Colorimetric BIOTIS / BIOTIS 82261 (Mayo)	1 mL frozen serum (red top tube). Separate serum from cells, put in separate plastic tube, and freeze. Store and transport frozen.	Biotinidase 3.5-13.8 U/L Partial deficiencies and carriers may occur at the low end of the reference range. Suggest maintenance on a biotin supplement and retesting in 1 month. Comment	NEW PROCEDURE Min. amt: 0.4 mL. Effective 8-19-03.
CARBOHYDRATE DEFICIENT TRANSFERRIN Affinity Chromatography/MS CDTRAN / CDTRAN 82373 (Mayo)	1 mL frozen serum (red top tube). Separate serum from cells and put in separate plastic tube and freeze. Store and transport frozen. Patient's age is required on request form for processing.	Mono-oligo/Di-oligo Ratio Normal 0.074 or less Indeterminate 0.075-0.109 A-oligo/Di-oligo Ratio Normal 0.022 or less Interpretation	NEW PROCEDURE Min. amt: 0.1 mL. Effective 8-19-03.
COPROPORPHYRIN ISOMERS I & III, UR HPLC COPISO / COPISO 84120 (Mayo)	50-mL frozen aliquot of a 24-hour urine collection. Add 5 g NA2CO3 at the start of collection to achieve a pH of GT 7.0. Send frozen in leakproof urine container. Store and transport frozen. The patient should be off medication for at least 1 week and abstain from alcohol and caffeine-containing beverages for at least 24 hours before and during the collection period. Protect specimen from light. Indicate total volume and collection period.	Collection period hrs Volume mL Coproporphyrin Isomers I & III Coproporphyrin I M 10-40 µg/24h F 2-30 Coproporphyrin III M 15-110 µg/24h F 6-80 % Coproporphyrin I 20-45 %	NEW PROCEDURE Min. amt: 20 mL. The preservative must be added before the start of collection. If patient is unable to be off medications, forward a list of medications with the specimen. Effective 8-19-03.

Test Method GA Workpar / SQ Code CPT Code(s)	Specimen Requirements	Reference Ranges	Comments Effective Date
GAD65 ANTIBODY ASSAY Immunoprecipitation Assay GAD65 / GAD65 86341 (Mayo)	1 mL serum (red top tube). Separate serum from cells and put in separate plastic tube. Store and transport refrigerated. Indicate source.	0.02 or less nmol/L	NEW PRODEDURE Other acceptable specimens: CSF. Effective 8-19-03.
GRANULOCYTE ANTIBODIES Indirect Immunofluorescence GRANAB / GRANAB 86021 (Mayo)	2 mL serum (red top tube). Separate serum from cells and put in separate plastic tube. Store and transport refrigerated.	Negative	NEW PRODEDURE Unacceptable conditions: serum from SST or gel-type tube. Post-transfusion specimens are not acceptable. Effective 8-19-03.
HMW KININOGEN (FITZGERALD FACTOR) ASSAY Clot FITGZ / FITGZ 85293 (Esoterix-Coag)	2 mL frozen citrated plasma (blue top tube). Separate plasma from cells and put in 2 separate plastic tubes and freeze. Store and transport frozen.	65-135%	NEW PRODEDURE Effective 8-19-03.
HOMOGENISTIC ACID, URINE (REFLEX) Manual Spot Test/Confirm GC/MS HOMOG / HOMOG 83917, 83921 if positive (Mayo)	5-mL frozen aliquot of a random urine collection, no preservatives. Put in leakproof plastic container and freeze. Store and transport frozen. This test may reflex to additional tests depending on the results. Additional charges may be added.	Homogentistic Acid, Urine Negative	NEW PRODEDURE Effective 8-19-03.
JC/BK VIRUS DETECTION BY PCR Real-time PCR JCBKPC / JCVKPC 87798 (Mayo)	For BK virus: 1 mL EDTA or ACD plasma (lavender or yellow top tube). Separate plasma from cells and put in plastic tube. Or 1 mL urine, random collection, in sterile container. Label as plasma or urine and refrigerate. For JC virus: 1 mL spinal fluid in sterile tube, refrigerated. Label as CSF. Store and transport refrigerated. Submit only one of the above specimens. A Mayo "Microbiology Request Form" must be submitted with the specimen. Indicate source.	Source Result Special Info Report Status This assay is performed using ASR reagents. It is performed pursuant to a license agreement with Roche Molecular Systems, Inc.	NEW PRODEDURE Unacceptable conditions: CSF that is grossly contaminated with blood, which may inhibit the PCR and produce false-negative results. Stability: less than 24 hours at room temperature. Effective 8-19-03.
MHPG, URINE (QUANT) HPLC MHPGUQ / MHPGUQ 82491 (Mayo)	5-mL aliquot of a 24-hour urine collection. Collect in plastic urine container (preferably polyethylene), no preservative. Refrigerate during collection. Aliquot into leakproof plastic urine container. Store and transport refrigerated.	0.9-3.5 mg/24h Therapeutic Indications Subclass I: LT 1.9 Subclass II: GT 2.5 Subclass III: 1.9-2.5 Additional information is present in the Mayo Medical Lab Handbook. Note: Creatinine values between 16-25 mg/kg/day verifies 24-hour collection if renal function is within the reference range. Collection period hrs Volume mL	NEW PRODEDURE Unacceptable conditions: random urine specimens. Effective 8-19-03.

Test Method GA Workpar / SQ Code CPT Code(s)	Specimen Requirements	Reference Ranges	Comments Effective Date
PORPHYRINS, TOTAL PLASMA Extraction & Scanning Fluorometry PORPPL / PORPPL 84311 (Mayo)	3 mL frozen heparin plasma (green top tube). Separate plasma from cells, put in separate plastic tube, and freeze. Store and transport frozen. Patient must be fasting for 12-14 hours and should be off medications for at least 1 week.	1 or less $\mu\text{g}/\text{dL}$ Concentrations GT 2 $\mu\text{g}/\text{dL}$ strongly suggest the existence of an abnormality in porphyrinogen metabolism or in clearance of porphyrinogen or porphyrin from blood.	NEW PROCEDURE Unacceptable conditions: PST tube. If patient cannot be off medications, forward a list of medications with specimen. Effective 8-19-03.
PREKALLIKREIN (FLETCHER FACTOR) Clot PREKAL / PREKAL 85292 (Esoterix-Coag)	2 mL frozen citrated plasma (blue top tube). Separate plasma from cells, put in two separate plastic tubes, and freeze. Store and transport frozen.	65-135 %	NEW PROCEDURE Effective 8-19-03.
ALPHA-GLOBIN GENE ANALYSIS Southern Blot and PCR ALGGA / ALGGA 83901, 83912, 83891, 83892 \times 3, 83894 \times 7, 83897 \times 2 (Mayo)	3 mL EDTA or ACD whole blood (lavender or yellow top tube), sent in the original Vacutainer tube. Invert several times to mix blood. Forward unprocessed whole blood promptly at room temperature. Specimens must arrive at Mayo within 72 hours of draw. Include a "Molecular Genetics Congenital Disorders Request Form" including relevant clinical and family history information. DO NOT USE THIS WORKPAR FOR PRENATAL SPECIMENS, AMNIOTIC FLUID, OR CHORIONIC VILLUS. Those specimens must be sent as reference specimens and have different specimen requirements. Include source.	Specimen Specimen ID Source Order date Method Result Interpretation Amendment Reviewed by Release date This test was developed and its performance characteristics determined by Laboratory Medicine and Pathology, Mayo Clinic Rochester. It has not been cleared or approved by the U.S. Food & Drug Administration.	NEW PROCEDURE Effective 8-19-03.